Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jürgen K. Rockstroh"'
Publikováno v:
Expert Opinion on Investigational Drugs. 20:537-548
The recent introduction of integrase inhibitors (INIs) into the HIV treatment armentarium has had a significant impact on HIV treatment. However, at present, raltegravir twice daily is the only licensed INI featuring a lower genetic barrier compared
Autor:
J Emmelkamp, Jürgen K. Rockstroh
Publikováno v:
Expert Opinion on Drug Safety. 7:559-569
Maraviroc represents the first licensed CCR5 co-receptor antagonist from the new antiretroviral (ARV) drug-class of entry inhibitors.Results of Phase III clinical trials in three-drug-class experienced patients have presented maraviroc as a promising
Autor:
Martin Vogel, Jürgen K. Rockstroh
Publikováno v:
Expert Opinion on Drug Safety. 4:403-420
Kaletra, a fixed-dose co-formulation of lopinavir/ritonavir, was the first boosted protease inhibitor developed for the treatment of HIV-infection. In September 2000, the US FDA granted Kaletra fast-track approval as data showed a higher efficacy in
Autor:
Ulrich Mey, Uwe Schlegel, Hendrik Pels, Rudolf Weiss, John Strehl, Ingo G.H. Schmidt-Wolf, Jürgen K. Rockstroh, Dieter Huhn
Publikováno v:
Expert Opinion on Pharmacotherapy. 4:1331-1343
Recently, the median survival of patients with AIDS-related lymphoma has changed significantly. This effect is mainly because of changes in the use of antiviral (highly active antiretroviral therapy; HAART) or chemotherapy regimens. Several novel tre